Primaquine-chitosan Nanoparticle Improves Drug Delivery to Liver Tissue in Rats

Abstract

Introduction:
 Primaquine is one of the essential medicines used to treat malaria due to Plasmodium vivax. Primaquine acts by eradicating hypnozoites in the liver, and its effect is dependent on the drug concentrations in the target tissue. The present study aimed to prepare primaquine in nanoparticle formulation using chitosan as carriers and improve on-target primaquine delivery to the liver.
 Methods: Primaquine-loaded chitosan nanoparticles were prepared using the ionic gelation method variations. Then, the resulting primaquine-chitosan nanoparticles were administered to the rats and compared with conventional primaquine. Afterward, plasma and liver concentrations of primaquine were quantified.
 Results: The primaquine-chitosan nanoparticles obtained were at 47.9 nm. The area under the curve for primaquine-chitosan nanoparticles resulted lower in the area under the curve (AUC) and Cmax, 0.46 and 0.42 times of conventional primaquine, respectively. However, no differences were found in time to reach Cmax (Tmax). Primaquine liver concentrations obtained with primaquine-chitosan nanoprimaquine resulted in 3 times higher than primaquine concentration.
 Conclusion: Enhanced drug delivery to rat liver tissue by primaquine-chitosan nanoparticles may improve on-target drug delivery to the liver, enhance primaquine ant hypnozoites effects, and reduce unwanted side effects in the circulation.

A nanochitosan-D-galactose formulation increases the accumulation of primaquine in the liver

“…Additional studies are necessary to determine the specific cell target of the NQ-Pq formulation. A recent study with primaquine-loaded chitosan nanoparticles obtained particles of much smaller size (47 nm), and oral administration to rats over 5 days also resulted in lower plasma Cmax but increased concentrations of primaquine in the liver ( 46 ).…”

Advancing liposome technology for innovative strategies against malaria

“…Characteristics of the active ingredient, such as half-life, distribution volume, solubility, and permeability, significantly influence the effectiveness of drugs, especially for preventive malaria therapy. In the hepatic phase of treatment, it is essential to have an active ingredient design capable of achieving high distribution in the liver to prevent the development of sporozoites in the liver into merozoites that infect red blood cells ( Louisa et al, 2022 ).…”

Chitosan nanoparticles improve the effectivity of miltefosine against Acanthamoeba

“…Chitosan has various pharmacological properties such as immune-potentiation, antioxidant, and antibacterial activities [ 18 ]. Chitosan nanoparticles (CS-NPs) have been employed as a drug delivery system to treat Plasmodium vivax and Leishmania [ 19 , 20 ]. As a mucoadhesive polymer, chitosan is a potential carrier to prolong the residence time and bioavailability of the encapsulated drugs on the ocular surfaces and enhance intraocular penetration.…”